Arcutis Biotherapeutics Inc

Overview

Arcutis Biotherapeutics Inc (Arcutis) is a biopharmaceutical company. It is focused on developing small molecules for the treatment of immune-mediated dermatological diseases and conditions. Its pipeline products include ARQ-151, a topical roflumilast cream for treating plaque psoriasis and atopic dermatitis (eczema); ARQ-154, a topical roflumilast foam against seborrheic dermatitis and scalp psoriasis; ARQ-252, a small molecule inhibitor of janus kinase type 1 (JAK1) to treat rheumatoid arthritis, psoriasis, Crohn’s disease and atopic dermatitis and ARQ-255 for inflammation in alopecia areata. The company is investigating novel dermatology treatments in inflammation and immunology diseases. Arcutis is headquartered in Westlake Village, California, the US.
Key Stats
Address
3027 Townsgate Road, Suite 300, Westlake Village, California
Headquarters

United States of America

Contact

1 805 4185006

Website
arcutis.com
No of Employees

54

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

ARQT [NASD]

Net Income (2020)

$-136 m

-223.8% (2020 vs 2019)
Market Cap *

$1,187 m

EPS *

$-3.8

  *Note: Ratios based on the share price as of 6-October-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Arcutis Biotherapeutics IncAbbVie Inc
Key Information
Headquarters United States of America United States of America
Headquarter City Westlake Village North Chicago
Headquarter State/Province California Illinois
No. of Employees 54 48,000
Entity Type Public Public

Products & Services

Arcutis is engaged in developing immuno-dermatology drugs. The key products under development offered by the company include the following:

Products
  • Products
  • ARQ-151:
  • Plaque Psoriasis and Atopic Dermatitis (eczema)
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2020 Stock Listings/IPO In January, the company announced its plans to raise US$100 million in IPO of shares.

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
29 Sep 2020 Arcutis Biotherapeutics Raises USD100 Million in Public Offering of Shares Equity Offering Arcutis Biotherapeutics Inc
29 Sep 2020 Arcutis Biotherapeutics Raises USD35 Million in Private Placement of Shares Private Equity Orbimed Advisors LLC Arcutis Biotherapeutics Inc
05 Jan 2018 Arcutis Enters into Option and License Agreement with Jiangsu Hengrui Medicine Licensing Agreement Arcutis Biotherapeutics Inc Jiangsu Hengrui Medicine Co Ltd